PPA
SPRY icon

Parametric Portfolio Associates’s ARS Pharmaceuticals SPRY Stock Holding History

Parametric Portfolio Associates’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$76K Sell
21,759
-18,759
-46% -$81.7K ﹤0.01% 3595
2021
Q4 		$270K Buy
+40,518
New +$329K ﹤0.01% 3316

Other funds holding SPRY

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Parametric Portfolio Associates's SPRY Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its ARS Pharmaceuticals (SPRY) stake by 46% in Q1 2022, selling an estimated $81.7K and leaving 21,759 shares worth $76K. The position accounts for ﹤0.01% of the portfolio, ranked #3595.

Parametric Portfolio Associates first reported a position in SPRY in Q4 2021 and has held it in 2 quarters since. The position peaked at $270K in Q4 2021. 70 funds tracked by Wall St. Rank hold SPRY as of Q1 2022.

  • Parametric Portfolio Associates held 21,759 shares of ARS Pharmaceuticals worth $76K as of Q1 2022.
  • Parametric Portfolio Associates sold 18,759 ARS Pharmaceuticals shares in Q1 2022, an estimated $81.7K.
  • ARS Pharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3595 holding.
  • Parametric Portfolio Associates first reported a position in ARS Pharmaceuticals in Q4 2021 and has held it in 2 quarters since.
  • Parametric Portfolio Associates's ARS Pharmaceuticals position peaked at $270K in Q4 2021.
  • 70 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.